Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (US)

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAAD) is a rare autoimmune inflammatory CNS disorder defined by IgG antibodies targeting the myelin oligodendrocyte glycoprotein. Its pathophysiology centers on antibody-mediated attacks against the myelin sheath, triggering acute demyelinating events that commonly present as bilateral optic neuritis, transverse myelitis, or pediatric acute disseminated encephalomyelitis. The current treatment landscape relies on off-label interventions. Acute attacks are managed with high-dose corticosteroids or plasma exchange, while relapsing cases are typically treated with maintenance immunosuppressants like rituximab, IVIG, or mycophenolate mofetil. A critical unmet need exists for FDA-approved, disease-specific therapies as well as biomarkers to predict which patients will remain monophasic versus those who require lifelong immunotherapy.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed MOGAAD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MOGAAD patients?
• How are tocilizumab and rituximab integrated into the treatment algorithm, and what is their source of business?
• What percentage of MOGAAD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of MOGAAD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Geography: United States

Key drugs covered: Rituximab, intravenous immunoglobulins, tocilizumab, Enspryng, Imaavy, Soliris, Vyvgart, Ultomiris, Rystiggo, corticosteroids

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.